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A commentary on
Successful therapies for Alzheimer’s dis-
ease: why so many in animal models and
none in humans?
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Drug development for Alzheimer’s dis-
ease (AD) has proven to be particularly
difficult. Only five symptomatic drugs
have been approved for its treatment
between 1993 and 2003. Despite great
efforts on research and huge investments
on drug development, no new treatments
have been approved for AD since 2003.
In particular, drug development success
rate has been staggering low with many
small molecules and immunotherapies
failing to show efficacy or superiority over
placebo in late clinical trials (Cummings
et al., 2014). Franco and Cedazo-Minguez
(2014) have recently addressed this critical
issue by underlying some highly relevant
open questions, some of which are briefly
discussed herein, especially regarding the
lack of predictive capability shown so far
by the available animal models for the
discovery of novel therapies.
Age-related neurodegenerative disor-
ders, including AD are largely human-
specific pathologies. Even though some
human brain aging aspects can be similarly
observed in aged non-human primates
and perhaps also in other mammalian
species, they do not readily develop the
full set of neuropathological and/or clin-
ical phenotypic features observed in the
human pathology. Nevertheless, cell and
animal models, including genetically
engineered non-mammalian species
(C. elegans, D. melanogaster, zebra fish)
have been remarkably useful in dissect-
ing the basic disease mechanisms and
for the screening of compounds directed
toward specific molecular pathways
involved in AD.
Historically, the AD field has been long
dominated by the characteristic pathologi-
cal hallmarks described by Alois Alzheimer
over a century ago: intraneuronal neu-
rofibrillary tangles (made up of tau fil-
aments) and extracellular senile plaques
(made up of Aβ peptide aggregates). A key
question remains to be answered though:
how these autopsy findings (endpoints of
the process) mechanistically relate with the
origin or cause of the disease? So far, ther-
apeutic strategies have been mainly driven
by pathology, with most drug develop-
ment efforts in the last twenty years hav-
ing been directed toward Aβ, essentially
focused on the amyloid cascade hypothe-
sis, with disappointing results until now.
On the other hand, tau-based strategies
(and targets other than Aβ) have received
little consideration until very recently
even though extensive tau pathology is
crucial to the disease and that recent
genetic studies have discovered mutations
within the tau gene leading to frontotem-
poral dementia, demonstrating that tau
dysfunction per se, in the absence of
amyloid pathology, is enough to cause
neurodegeneration and clinical dementia.
During the last decade, the study of
the genetics of familial AD (FAD) has
provided a wealth of knowledge on the
elements that affect the molecular mech-
anisms underlying AD pathogenesis and
established that, apart from the age of
onset, sporadic AD is clinically and neu-
ropathologically similar to the most com-
mon familial forms. These phenotypic
resemblance has inspired the development
of a wide variety of genetically modified
cellular and animal models, based on the
mutations present in FAD. Genetics of
FAD has also provided the strongest sup-
port for a critical role for Aβ in AD patho-
physiology, but the fact that some of the
mutations in presenilin 1 (PS1), the most
commonly mutated gene in FAD, are not
directly related to Aβ pathology suggests
that there is something else to it.
Albeit theymight not be the best species
for mimicking the human disease, trans-
genic mice are still undoubtedly the most
popular and extensively used animal mod-
els for studying AD. The studies carried
on in animal models have also rendered
invaluable information on the pathogene-
sis and pathophysiology of AD including,
for instance, novel insights into the molec-
ular mechanisms underlying the patho-
logical aggregation of pivotal proteins, the
pathways toward neuronal damage, the
contribution of genetic risk factors and
the role of neuroinflammation in neurode-
generation. Yet, these models appears to
have contributed only partially to shed
light on the actual mechanisms trigger-
ing the disease, thus preventing a true
translation into new therapies, diagnosis
and prevention. Even though an impres-
sive amount of knowledge has been gen-
erated from the use of animal models, it
has only marginally enriched our thera-
peutic potential. Actually, the hopes often
raised by encouraging preclinical results
have evanesced when the new strategies
have been tested in clinical trials.
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Besides an excessive focus on the amy-
loid cascade hypothesis as paramount in
AD pathogenesis and a lack of integration
of a large body of other data relevant to
the emergence of clinical AD,methodolog-
ical issues related to clinical trials might all
have contributed for the failure to trans-
late successful results from animal mod-
els into clinical trials. The latter has been
recently started to be addressed by the new
NIA-AA guidelines for diagnostic of AD
(McKhann et al., 2011) and mild cognitive
impairment (MCI) (Albert et al., 2011) as
well as the recognition of preclinical AD
as a newly defined stage (Sperling et al.,
2011) based on recent evidence show-
ing some biomarker changes many years
prior to the onset of clinical symptoms.
All this has led to an increasing inter-
est in testing drugs (that already failed in
late clinical trials) in prevention trials in
FAD subjects, with the hope that begin-
ning the treatment earlier might prove
efficacious (Reiman et al., 2011; Carrillo
et al., 2013). Furthermore, development of
solid, reproducible biomarkers may help
the current clinical outcomes based solely
on cognition and facilitate drug devel-
opment of disease-modifying drugs. On
the other hand, as stated by Franco and
Cedazo-Minguez (2014) in Table 2, limited
knowledge of the specific features of the
countless animal models generated may
also have contributed to the lack of suc-
cess in translating preclinical research into
clinical application.
A number of complexity elements must
be kept in mind when trying to model
AD in animals: (i) Genetics (mutations,
risk-associated common variants sporadic
forms, epigenetics); (ii) Environment
(toxins, diet, stress, social interactions,
infections); and (iii) Aging (metabolic
changes, hormones, genomic instability,
accumulation of damaging insults). Most
of the currently used models are not able
to recreate the complexity of the human
disease since they only take into account
these factors individually. However, the
combined analysis of these factors and the
evaluation of their exact contribution to
the development of the pathology is most
suitable in animal models and cannot be
fully accomplished in cellular or ex-vivo
models. Thus, in order to better figure out
the significance of the interplay among
different neural cells and circuits, the next
generation of animal models must repro-
duce the human disease more precisely.
Together with further understanding
of the molecular mechanisms involved
and better, clinically relevant readouts it
should greatly help improving predictabil-
ity in translating efficacy results in animal
models to the clinical setting.
Finally, in light of recent developments
of in silico approaches to modeling of at
least some aspects of brain function, we
would like to further emphasize the essen-
tial role of experimental models to dissect
pathogenic mechanisms and to support
preclinical drug development.
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